Hong Kong needs new funding model to draw investment from global drug makers: AstraZeneca

Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca

HK24H 僅展示標題與短摘要，全文版權歸 SCMP Business 所有。